What is Formosa Pharmaceuticals licensing to Rxilient Medical?

Formosa Pharmaceuticals is licensing Byqlovi, a clobetasol propionate ophthalmic suspension for post-ocular surgery recovery, to Rxilient Medical.

When was APP13007 approved by the FDA?

APP13007, known as Byqlovi, was approved by the US Food and Drug Administration in 2024.

Home / Business and Economy / Formosa Pharma & Rxilient Ink Eye Drug Deal

Formosa Pharma & Rxilient Ink Eye Drug Deal

Q: Which ASEAN markets will Byqlovi be available in?

Byqlovi will be available in Thailand, Singapore, the Philippines, and Indonesia through the licensing agreement.

4 Dec

•

Summary

Formosa Pharmaceuticals and Rxilient Medical inked a deal for eye drug Byqlovi.
The drug, APP13007, treats inflammation and pain after ocular surgery.
APP13007, approved by the FDA in 2024, offers twice-daily dosing.

Formosa Pharma & Rxilient Ink Eye Drug Deal

Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement, paving the way for the commercialization of Byqlovi, clobetasol propionate ophthalmic suspension, 0.05% (APP13007), across several Association of Southeast Asian Nations (ASEAN) markets.

This strategic partnership grants Rxilient Medical the rights to market APP13007 in Thailand, Singapore, the Philippines, and Indonesia. The patented medicine is designed to treat inflammation and pain experienced by patients following ocular surgery. The deal includes upfront payments and sales and regulatory milestones.

APP13007, which received US FDA approval in 2024, utilizes Formosa's advanced particle nanotech (APNT) formulation. This innovative approach allows for a convenient twice-daily dosing schedule over 14 days, providing sustained and rapid relief for patients recovering from eye surgery.